{"id":"https://openalex.org/W3131553692","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-15","title":"Abstract PS11-15: Plinabulin and pegfilgrastim (Plin+Peg) versus peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain","display_name":"Abstract PS11-15: Plinabulin and pegfilgrastim (Plin+Peg) versus peg monotherapy (Peg) after TAC: A comparison of efficacy, safety, relative dose intensity (RDI) and bone pain","publication_year":2021,"publication_date":"2021-02-15","ids":{"openalex":"https://openalex.org/W3131553692","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-15","mag":"3131553692"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.sabcs20-ps11-15","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-15","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-15","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5061736755","display_name":"Douglas W. Blayney","orcid":"https://orcid.org/0000-0002-7931-4533","observed_orcids":["https://orcid.org/0000-0002-7931-4533"]},"institutions":[{"id":"https://openalex.org/I4390039303","display_name":"Stanford Cancer Institute","ror":"https://ror.org/014qe3j22","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210137306","https://openalex.org/I4390039303","https://openalex.org/I97018004"]},{"id":"https://openalex.org/I97018004","display_name":"Stanford University","ror":"https://ror.org/00f54p054","country_code":"US","type":"education","lineage":["https://openalex.org/I97018004"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Douglas W. Blayney","raw_affiliation_strings":["1Stanford Cancer Institute, Stanford, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Stanford Cancer Institute, Stanford, CA;","institution_ids":["https://openalex.org/I4390039303","https://openalex.org/I97018004"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Greg Ginn","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I55820996","display_name":"Wake Technical Community College","ror":"https://ror.org/03c69q147","country_code":"US","type":"education","lineage":["https://openalex.org/I55820996"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Greg Ginn","raw_affiliation_strings":["2Statogen Consulting,LLC, Wake Forest, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Statogen Consulting,LLC, Wake Forest, NC;","institution_ids":["https://openalex.org/I55820996"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070754234","display_name":"Lan Huang","orcid":"https://orcid.org/0000-0002-3140-4687","observed_orcids":["https://orcid.org/0000-0002-3140-4687"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Lan Huang","raw_affiliation_strings":["3Beyond Spring Pharmaceuticals, Inc., New York, NY;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Beyond Spring Pharmaceuticals, Inc., New York, NY;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015687794","display_name":"Ramon W. Mohanlal","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ramon W. Mohanlal","raw_affiliation_strings":["4Beyond Spring Pharmaceuticals,Inc., New York, NY"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Beyond Spring Pharmaceuticals,Inc., New York, NY","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"81","issue":"4_Supplement","first_page":"PS11","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T12172","display_name":"Neutropenia and Cancer Infections","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11752","display_name":"Cancer Treatment and Pharmacology","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12919","display_name":"Blood disorders and treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/plinabulin","display_name":"plinabulin","score":0.9990000128746033},{"id":"https://openalex.org/keywords/pegfilgrastim","display_name":"pegfilgrastim","score":1.0},{"id":"https://openalex.org/keywords/chemotherapy-induced-neutropenia","display_name":"chemotherapy-induced neutropenia","score":0.8930000066757202},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.7689999938011169},{"id":"https://openalex.org/keywords/docetaxel","display_name":"docetaxel","score":0.6899999976158142},{"id":"https://openalex.org/keywords/doxorubicin","display_name":"doxorubicin","score":0.9890000224113464},{"id":"https://openalex.org/keywords/cyclophosphamide","display_name":"cyclophosphamide","score":0.9990000128746033},{"id":"https://openalex.org/keywords/febrile-neutropenia","display_name":"febrile neutropenia","score":0.8109999895095825},{"id":"https://openalex.org/keywords/relative-dose-intensity","display_name":"relative dose intensity","score":0.8240000009536743},{"id":"https://openalex.org/keywords/bone-pain","display_name":"bone pain","score":0.968999981880188},{"id":"https://openalex.org/keywords/neutropenia-duration","display_name":"neutropenia duration","score":0.4690000116825104},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.30399999022483826},{"id":"https://openalex.org/keywords/granulocyte-colony-stimulating-factor","display_name":"granulocyte colony-stimulating factor","score":0.7289999723434448}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8686470985412598},{"id":"https://openalex.org/C2778658803","wikidata":"https://www.wikidata.org/wiki/Q1592932","display_name":"Pegfilgrastim","level":5,"score":0.7592693567276001},{"id":"https://openalex.org/C2777063308","wikidata":"https://www.wikidata.org/wiki/Q1435822","display_name":"Neutropenia","level":3,"score":0.6738616228103638},{"id":"https://openalex.org/C54400483","wikidata":"https://www.wikidata.org/wiki/Q1793202","display_name":"PEG ratio","level":2,"score":0.5757179856300354},{"id":"https://openalex.org/C2778850193","wikidata":"https://www.wikidata.org/wiki/Q3775974","display_name":"Febrile neutropenia","level":4,"score":0.5666797161102295},{"id":"https://openalex.org/C2777767877","wikidata":"https://www.wikidata.org/wiki/Q419327","display_name":"Granulocyte colony-stimulating factor","level":3,"score":0.527969479560852},{"id":"https://openalex.org/C74133956","wikidata":"https://www.wikidata.org/wiki/Q4669824","display_name":"Absolute neutrophil count","level":4,"score":0.5016241073608398},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4408060908317566},{"id":"https://openalex.org/C2781190966","wikidata":"https://www.wikidata.org/wiki/Q420436","display_name":"Docetaxel","level":3,"score":0.4407365322113037},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.41392314434051514},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.3890302777290344},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.sabcs20-ps11-15","doi":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-15","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.sabcs20-ps11-15","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2984749858","https://openalex.org/W4206195540","https://openalex.org/W2947292239","https://openalex.org/W3095561524","https://openalex.org/W2947778483","https://openalex.org/W3171295247","https://openalex.org/W3129386684","https://openalex.org/W3170098415","https://openalex.org/W3171922292","https://openalex.org/W2978491094"],"abstract_inverted_index":{"Abstract":[0],"Introduction:Prevention":[1],"of":[2,35,178,217,257,371,378,452,465],"Chemotherapy":[3],"Induced":[4],"Neutropenia":[5],"(CIN)":[6],"through":[7],"primary":[8,47],"or":[9,204,273],"secondary":[10],"prophylaxis":[11],"is":[12,21,413],"indicated":[13],"in":[14,37,69,86,139,163,356,396],"breast":[15],"cancer":[16],"(BC)":[17],"chemotherapy":[18],"(chemo)":[19],"which":[20,60],"administered":[22],"with":[23,46,103,107,158,161,169,186,259,276,287,302,365],"curative":[24],"intent.":[25],"Granulocyte":[26],"colony":[27],"stimulating":[28],"factors":[29],"(G-CSFs),":[30],"including":[31],"Peg":[32,104,116,160,200,205,279,290,305,316,374,394,411],"are":[33],"standard":[34,392],"care":[36],"this":[38,397],"context.":[39],"In":[40,172,312],"typical":[41],"every":[42],"three-week":[43],"chemo":[44,91,106],"regimens":[45],"G-CSF":[48],"prophylaxis,":[49],"absolute":[50,230],"neutrophil":[51,120,225,231],"count":[52],"(ANC)":[53],"nadir":[54,83,226,298],"occur":[55],"approximately":[56],"day":[57,293],"(D)":[58],"7,":[59,240],"reduces":[61],"but":[62],"does":[63],"not":[64],"eliminate":[65],"febrile":[66,110],"neutropenia":[67,111,214,222,275],"risk":[68],"the":[70,82,87,98,119,153,173,313,466],"first":[71],"week.":[72],"However,":[73],"plinabulin":[74],"(Plin),":[75],"a":[76,108,253],"novel":[77],"non-G-CSF":[78],"agent,":[79],"protects":[80],"against":[81,387],"and":[84,115,155,192,196,220,224,262,342,384,441,459],"CIN":[85],"1st":[88],"week":[89],"after":[90,105,448],"(Blayney":[92,131],"ASCO":[93],"2019).":[94],"These":[95],"findings":[96],"provided":[97],"rationale":[99],"to":[100,373,391],"combine":[101],"Plin":[102,114,134,162,372],"high":[109],"risk.":[112],"Both":[113,122],"act":[117],"on":[118,234],"precursor.":[121],"agents":[123],"mobilize":[124],"bone":[125,388,460],"marrow-derived":[126],"CD34+":[127],"progenitor":[128],"stem":[129],"cells":[130],"ASH":[132],"2018).":[133],"has":[135,375],"also":[136],"anti-cancer":[137],"efficacy":[138,154],"an":[140],"animal":[141],"BC":[142,166,182],"model":[143],"(Bertelsen,":[144],"Int":[145],"J":[146],"Rad":[147],"Biol":[148],"2011).":[149],"Here":[150],"we":[151],"summarize":[152],"safety":[156],"data":[157],"combining":[159],"potentially":[164],"curable":[165],"patients":[167,183],"treated":[168,185],"TAC.":[170],"Methods:":[171],"randomized":[174,398],"phase":[175,399],"2":[176,335,400],"portion":[177],"Study":[179],"106":[180],"(NCT0329457),":[181],"were":[184],"TAC":[187],"(docetaxel":[188],"75,":[189],"doxorubicin":[190],"50":[191],"cyclophosphamide":[193],"500":[194],"mg/m2)":[195],"either":[197,357],"6":[198],"mg":[199],"alone":[201,395,412],"(Peg6;":[202],"n=22),":[203],"6mg+Plin":[206],"20":[207],"mg/m2":[208],"(Plin+Peg;":[209],"n=16).":[210],"Grade":[211],"(Gr)":[212],"3/4":[213],"frequency,":[215],"duration":[216],"Gr":[218,271,318,326,334,343,352],"3":[219,272,327,406],"4":[221,274,319],"(DSMN),":[223],"was":[227,250,268,280,291,306,322,330,338,347,361],"calculated":[228],"from":[229],"counts":[232],"obtained":[233],"days":[235],"0,":[236],"1,":[237],"3,":[238],"6,":[239],"8,":[241],"9,":[242],"10,":[243],"11,":[244],"12,":[245],"13,":[246],"15.":[247],"Bone":[248,359],"pain":[249,360,389,461],"assessed":[251],"by":[252],"validated":[254],"questionnaire.":[255],"Percentage":[256],"pts":[258],"RDI":[260,383],"<85%":[261],"adverse":[263],"event":[264],"rate":[265],"(Grades":[266],"1-5)":[267],"calculated.":[269],"Results:":[270],"Plin/Peg":[277,288,303],"vs":[278,282,289,294,304,309,315,324,332,340,349,367,410],"50%":[281],"81.1%":[283],"(p<0.04).":[284],"Median":[285],"DSMN":[286],"0.5":[292],"1":[295,344],"day.":[296],"ANC":[297],"[mean":[299],"(95%":[300],"CI)]":[301],"1.15":[307],"(0.66;1.65)":[308],"0.80":[310],"(0.37;1.22).":[311],"Plin+Peg":[314,366,409],"group,":[317],"AE":[320,328,336,345],"frequency":[321,329,337,346],"37.3%":[323],"54.5%,":[325],"18.8%":[331,348],"27.3%,":[333],"25%":[339],"9.1%":[341],"4.5%.":[350],"No":[351],"5":[353],"AEs":[354],"occurred":[355],"group.":[358],"significantly":[362],"less":[363],"(P<0.001)":[364],"Peg.":[368],"Conclusion:":[369],"Addition":[370],"superior":[376,380,382,385],"prevention":[377],"CIN,":[379],"safety,":[381,454],"protection":[386],"compared":[390],"dose":[393,456],"trial.":[401],"A":[402,450],"confirmatory":[403],"global":[404],"Phase":[405],"trial":[407],"comparing":[408],"underway.":[414],"RDI<85%Cycle":[415],"1Cycle":[416],"2Cycle":[417],"3Cycle":[418],"4Peg0":[419],"%13.6":[420],"%19.1":[421,422],"%Plin+Peg0":[423],"%6.25":[424,425,426],"%":[427],"Citation":[428],"Format:":[429],"Douglas":[430],"W.":[431,438],"Blayney,":[432],"Greg":[433],"Ginn,":[434],"Lan":[435],"Huang,":[436],"Ramon":[437],"Mohanlal.":[439],"Plinabulin":[440],"pegfilgrastim":[442],"(Plin+Peg)":[443],"versus":[444],"peg":[445],"monotherapy":[446],"(Peg)":[447],"TAC:":[449],"comparison":[451],"efficacy,":[453],"relative":[455],"intensity":[457],"(RDI)":[458],"[abstract].":[462],"In:":[463],"Proceedings":[464],"2020":[467,474],"San":[468,477],"Antonio":[469],"Breast":[470],"Cancer":[471,483],"Virtual":[472],"Symposium;":[473],"Dec":[475],"8-11;":[476],"Antonio,":[478],"TX.":[479],"Philadelphia":[480],"(PA):":[481],"AACR;":[482],"Res":[484],"2021;81(4":[485],"Suppl):Abstract":[486],"nr":[487],"PS11-15.":[488]},"counts_by_year":[],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2021-03-01T00:00:00"}